Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PsiThera-sTNFα is an oral small-molecule inhibitor of soluble tumor necrosis factor alpha (sTNFα) currently in the discovery stage of development by PsiThera. Designed as an "Antibody-in-a-Pill," the therapeutic aims to provide the potent, high-affinity blockade of TNFα typically associated with injectable monoclonal antibodies but in a more convenient oral format. The program utilizes a proprietary platform that combines physics-based modeling, artificial intelligence, and structural biology to target complex cytokine systems where biologics have traditionally dominated. It is being developed for the treatment of autoimmune and inflammatory conditions, specifically within the fields of rheumatology and inflammatory bowel disease (IBD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PsiThera-sTNFα.